Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

IF 3.5 2区医学 Q1 OPHTHALMOLOGY

British Journal of Ophthalmology Pub Date : 2025-05-24 DOI:10.1136/bjo-2025-327410

Jurgen Sota, Luciana Breda, Maria Pia Paroli, Soad Hashad, Alejandra de-la-Torre, Silvana Guerriero, Abdurrahman Tufan, Juanita Cardona-López, María José Altamar-García, Saverio La Bella, Antonio Vitale, Edoardo Biancalana, Emanuela Del Giudice, Francesca Minoia, Sulaiman Al-Mayouf, Bruno Frediani, Luca Cantarini, Claudia Fabiani

{"title":"Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders","authors":"Jurgen Sota, Luciana Breda, Maria Pia Paroli, Soad Hashad, Alejandra de-la-Torre, Silvana Guerriero, Abdurrahman Tufan, Juanita Cardona-López, María José Altamar-García, Saverio La Bella, Antonio Vitale, Edoardo Biancalana, Emanuela Del Giudice, Francesca Minoia, Sulaiman Al-Mayouf, Bruno Frediani, Luca Cantarini, Claudia Fabiani","doi":"10.1136/bjo-2025-327410","DOIUrl":null,"url":null,"abstract":"To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes. Data are available upon reasonable request. The data underlying this article will be shared upon reasonable request to the corresponding author.","PeriodicalId":9313,"journal":{"name":"British Journal of Ophthalmology","volume":"34 1","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bjo-2025-327410","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported. The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes. Data are available upon reasonable request. The data underlying this article will be shared upon reasonable request to the corresponding author.

查看原文本刊更多论文

托珠单抗在儿童非感染性葡萄膜炎中的有效性：来自国际AIDA网络注册的眼部炎症性疾病数据

描述托珠单抗（TCZ）在15例难治性非感染性葡萄膜炎患儿中的疗效。报告的结果是治疗前后的复发次数，类固醇保留效果和药物保留率。黄斑水肿，荧光造影结果和眼部并发症也有报道。平均眼部复发数由314 / 100眼/年显著下降至106 / 100眼/年（p=0.016）。检测到显著的类固醇节约效应（p=0.037）。随访6个月时TCZ药物生存率为77.4%，随访12、24、36个月时为61.9%。所有受累眼睛的黄斑水肿和视网膜血管炎均消失。如有合理要求，可提供资料。本文的数据基础将在合理的要求下分享给通讯作者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Ophthalmology 医学-眼科学

CiteScore

10.30

自引率

2.40%

发文量

213

审稿时长

3-6 weeks

期刊介绍： The British Journal of Ophthalmology (BJO) is an international peer-reviewed journal for ophthalmologists and visual science specialists. BJO publishes clinical investigations, clinical observations, and clinically relevant laboratory investigations related to ophthalmology. It also provides major reviews and also publishes manuscripts covering regional issues in a global context.